Company Filing History:
Years Active: 2014
Title: The Innovations of Torsten Liersch
Introduction
Torsten Liersch is a notable inventor based in Goettingen, Germany. He has made significant contributions to the field of medical research, particularly in the area of cancer treatment. His work focuses on improving the understanding of rectal adenocarcinomas and their response to therapies.
Latest Patents
Liersch holds a patent for a composition that aids in detecting the response of rectal adenocarcinomas to radiochemotherapy. The patent describes the use of a cDNA array consisting of 9984 genes for expression profiling in rectal adenocarcinoma. The expression data obtained from this array were correlated with the responsiveness to chemotherapy followed by radiotherapy. A set of 54 genes was identified as being differentially expressed in responders compared to non-responders. These genes may serve as prognostic markers to determine whether a rectal adenocarcinoma is responsive to radiochemotherapy.
Career Highlights
Torsten Liersch is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to contribute to groundbreaking research in cancer treatment and diagnostics.
Collaborations
Liersch has collaborated with esteemed colleagues such as Thomas Ried and Michael J Difilippantonio. Their combined expertise has furthered the research in the field of oncology and improved the understanding of cancer therapies.
Conclusion
Torsten Liersch's innovative work in cancer research, particularly regarding rectal adenocarcinomas, showcases the importance of scientific advancements in medical treatments. His contributions through patents and collaborations highlight the ongoing efforts to improve patient outcomes in oncology.